Ohashi Rina, Kato Motoyasu, Katsura Yoko, Takekawa Hidenori, Hoshika Yoshito, Sugawara Tomonori, Yoshimi Kaku, Togo Shinsaku, Nagaoka Tetsutaro, Seyama Kuniaki, Takahashi Kazuhisa, Tsuchiya Koji, Misawa Shigeki, Kikuchi Ken
Department of Respiratory Medicine, Juntendo University.
Med Mycol J. 2011;52(1):33-8. doi: 10.3314/jjmm.52.33.
Breakthrough non- Aspergillus mold infections among patients receiving the anti-mold azole antifungal agents like voriconazole or posaconazole have been increasingly reported. We report a case of lung Scedosporium prolificans infection with multiple cavities in a 58-year-old man with monoclonal gammopathy of undetermined significance (MGUS) during voriconazole treatment for probable invasive aspergillosis. Cultures of repeated sputum specimens yielded the same fungus until his death 83 days after diagnosis. S. prolificans should be considered in patients with breakthrough infections receiving voriconazole.
接受伏立康唑或泊沙康唑等抗霉菌唑类抗真菌药物治疗的患者中,非曲霉菌突破性霉菌感染的报道日益增多。我们报告一例58岁意义未明的单克隆丙种球蛋白病(MGUS)男性患者,在接受伏立康唑治疗可能的侵袭性曲霉菌病期间发生肺部多育赛多孢菌感染并伴有多个空洞。反复痰标本培养均检出同一真菌,直至诊断后83天患者死亡。接受伏立康唑治疗出现突破性感染的患者应考虑多育赛多孢菌感染。